Intracellular free cholesterol

Intracellular free cholesterol refers to the pool of unesterified cholesterol present within cells. It is an essential lipid component that maintains membrane structure and fluidity, serves as a precursor for steroid hormones and bile acids, and participates in the regulation of gene expression through sterol regulatory element-binding proteins (SREBPs) and liver X receptors (LXRs)[1][2][3]. Cells acquire it via uptake from plasma lipoproteins or de novo synthesis. To avoid toxicity from excess levels—since unesterified/free forms are particularly harmful—cells tightly regulate its concentration by converting it into cholesteryl esters for storage or exporting it via transporters such as ABCA1/ABCG1[2][3]. Disruption in this balance leads to pathological states such as foam cell formation during atherogenesis; excessive accumulation triggers cellular stress responses including increased phospholipid synthesis, leakage of cellular contents due to membrane damage, apoptosis, necrosis, or crystal formation—all features observed in cardiovascular diseases like atherosclerosis[7]. While drugs can modulate its levels indirectly by targeting enzymes involved in esterification or trafficking proteins affecting distribution among organelles, "intracellular free cholesterol" itself is not considered a classical therapeutic target like an enzyme or receptor but rather represents an important metabolic intermediate whose dysregulation underlies several disease processes[1][2][5][7].

Other names

Free cholesterolUnesterified cholesterolCellular free cholesterol

ACAT inhibitors prevent esterification of free cholesterol, leading to accumulation of intracellular free cholesterol[7]. U18666A alters intracellular trafficking and sequesters free cholesterol in a non-toxic pool[7].